Skip to main content

Day: July 18, 2025

Beneficient Receives Nasdaq Listing Determination

Will Request Hearing DALLAS, July 18, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform AltAccess, today announced that on July 16, 2025, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that, due to its continued non-compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the delay in the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025 with the Securities and Exchange Commission, in contravention of Nasdaq’s periodic reporting requirement set forth in Nasdaq Listing Rule 5250(c)(1), the Company’s securities...

Continue reading

Optiva Inc. enters into Support Agreement with Holders of Approximately 85% of Outstanding Senior Secured Notes to Provide 45-Day Period to Continue Negotiations with Noteholders and Third Parties regarding a Potential Transaction

Optiva is in negotiations with its existing noteholders and certain third parties regarding a potential transaction that would result in the exchange of Optiva’s outstanding notes for a combination of shares and new notes of a proforma merged strategic third party (a “Potential Transaction“). Optiva will continue operating its business as usual, fulfilling all ongoing commitments to customers, employees, and suppliers. Based on the proposals received to date, Optiva’s common shareholders are expected to receive nominal consideration for their shares in connection with any Potential Transaction.TORONTO, July 18, 2025 (GLOBE NEWSWIRE) — Optiva Inc. (TSX: OPT) (“Optiva” or the “Company“), a leader in powering the telecom industry with cloud-native billing, charging and revenue management...

Continue reading

AYR Wellness Announces Further Extension of Limited Waiver Agreement with Senior Noteholders

MIAMI, July 18, 2025 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, today announces that it has entered into an additional amendment to its previously disclosed Limited Waiver Agreement with the holders of a majority of its senior secured notes (the “Majority Holders”). This latest amendment extends the temporary waiver period to July 25, 2025, providing the Company with further time and flexibility to continue ongoing negotiations with its senior lenders and to further pursue strategic options to strengthen its capital structure. As previously disclosed, under the Limited Waiver Agreement, the Majority Holders have provided a waiver of certain events of default related to the Company’s delay in filing...

Continue reading

Matador Technologies Provides Contract Details for CTO Engagement

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) — Further to its March 31, 2025 announcement welcoming Antoine De Vuyst as Chief Technology Officer (“CTO”) and lead designer of the forthcoming Digital Gold Platform on Bitcoin, Matador Technologies Inc. (TSXV: MATA, OTCQB: MATAF, FSE: IU3) (“Matador” or the “Company”) is providing the following summary of Mr. De Vuyst’s consulting agreement (the “Agreement“), as requested by the TSX Venture Exchange (the “TSXV”). Under the Agreement, which took effect March 1, 2025, Mr. De Vuyst serves as CTO on a month-to-month basis and devotes the time required to meet Matador’s product-development milestones. As consideration for his services as CTO, Mr. De Vuyst will receive:C$5,000 per month in common shares of the Company, calculated quarterly, using the 30-day volume-weighted average...

Continue reading

Pyrophyte Acquisition Corp. II Announces Closing of $175 Million Initial Public Offering

HOUSTON, TX, July 18, 2025 (GLOBE NEWSWIRE) — Pyrophyte Acquisition Corp. II (NYSE: PAII) (the “Company”) today announced the closing of its initial public offering of 17,500,000 units at a public offering price of $10.00 per unit. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. The units are listed on the New York Stock Exchange (the “NYSE”) and commenced trading under the ticker symbol “PAII.U” on July 17, 2025. Once the securities comprising the units begin separate trading, the Class A ordinary shares and the warrants are expected to be listed on NYSE under the symbols “PAII” and “PAII WS,” respectively. Concurrently with the closing of the initial public offering, the Company...

Continue reading

Gray Announces Revolving Credit Facility increase to $750 million and extension to 2028

ATLANTA, July 18, 2025 (GLOBE NEWSWIRE) — Gray Media, Inc. (“Gray” or the “Company”) (NYSE: GTN) today announced that it has (i) increased the aggregate commitments under its revolving credit facility (the “Revolving Credit Facility”) by $50 million, resulting in aggregate commitments under the Revolving Credit Facility of $750 million, and (ii) extended the maturity date of the Revolving Credit Facility from December 1, 2027 to December 1, 2028.  In connection with the amendment and the previously announced offering of $900 million aggregate principal amount of 9.625% senior secured second lien notes due 2032 (the “Notes”), there is $700 million of undrawn availability under the Revolving Credit Facility (excluding approximately $8 million of outstanding letters of credit). The Revolving Credit Facility is available on a revolving...

Continue reading

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the Board of Directors granted Qing Zuraw, M.D., the Company’s Chief Development Officer, 4,373,040 stock options and 937,080 restricted stock units (“RSUs”) in connection with the commencement of her employment. The foregoing stock option and RSU awards were granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). The stock options have a ten-year term and an exercise price of $2.38 per share, which is equal to the closing price of Vor Bio’s...

Continue reading

Rogers Announces Pricing of Cash Tender Offers for Eight Series of U.S. Dollar Debt Securities

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) — Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) today announced the pricing terms of its previously announced separate offers (the “Offers”) to purchase for cash any and all of the outstanding notes of each series listed in the table below (collectively, the “Notes”), up to a maximum of US$1,250,000,000 aggregate Total Consideration (as defined below). Subject to the Consideration Cap Condition (as defined below), the series of Notes that are purchased in the Offers will be based on the acceptance priority levels (each, an “Acceptance Priority Level”) set forth in the table below. If a given series of Notes is accepted for purchase pursuant to the Offers, all Notes of that series that are validly tendered and not validly withdrawn will be accepted...

Continue reading

HPQ Silicon Cancels 5,335,000 Stock Options

MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, announces that its Board of Directors has approved the cancellation of 5,335,000 stock options. These options were set to expire on December 20, 2026, with an exercise price of $1.00. None of the options in this series had been exercised. NOTICE OF CLAIM The Company also wishes to inform shareholders that it has received today a claim for payment in the amount of €29,000 in cash, along with an additional claim for €180,000 to be paid in Company shares. These claims arise from a draft agreement dated August 2022 that was never signed or ratified by the Company. HPQ management believes it has strong grounds to dispute...

Continue reading

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market (“Nasdaq”) and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act. In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Purchase Agreement”) with Gilead Sciences, Inc. (“Gilead”) pursuant...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.